Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Gynecologic 1

Conditions

Gynecologic Cancer 1

Interventions

Paclitaxel 150Carboplatin 110Cisplatin 95Bevacizumab 42Topotecan 39Gemcitabine 38liposomal doxorubicin 34Radiotherapy 29Doxorubicin 27Brachytherapy 26Taxes 24pembrolizumab 20olaparib 20Drug Therapy 20Hyperthermic Intraperitoneal Chemotherapy 16Chemotherapy, Adjuvant 16human papillomavirus vaccine, L1 type 16, 18 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14Docetaxel 13Neoadjuvant Therapy 12Platinum 10niraparib 9Radiation 91,2-diaminocyclohexaneplatinum II citrate 9Vaccines, Synthetic 8Surgical Procedures, Operative 8atezolizumab 7Specimen Handling 7Papillomavirus Vaccines 7Letrozole 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Prochlorperazine × Gynecologic × Clear all
NCT04503668 2025-06-18

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

University of Michigan Rogel Cancer Center

Phase 3 Terminated
62 enrolled 16 charts
Gynecologic

Gynecologic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡